Connect to other sites within the UBM Medica Network
The sodium glucose cotransporter-2 inhibitors are the newest diabetes drugs available. Have you got the basic concepts under your belt? Try these 6 questions and find out.
SGLT2 Inhibitors and Fracture Risk: A Review of What We Know
It's probably too early to pass judgment but data from clinical trials point to decreased bone mineral density and increased treatment-emergent fractures in patients taking the new antidiabetes drugs.
Have You Heard This (Week's) News?
Microbes in the gut affect metabolic pathways involved in the pathogenesis of obesity, insulin resistance, and diabetes. Antibiotics can alter gut microbiota.
Aflibercept (Eylea, Regeneron Pharmaceuticals), a second ophthalmic vascular endothelial growth factor inhibitor, has received FDA approval for the treatment of diabetic retinopathy in patients with diabetic macular edema.
Poor GLP-1 Response Seen Before Type 2 Diabetes Develops
A Danish study found reduced endogenous levels of glucagon-like peptide-1 in persons with prediabetes. Perhaps the incretin system defect comes first.
Do You Speak DPP-4I?
There are 10 FDA-approved DPP-4 inhibitors--single agents and combination products. Do you speak their language? Find out with these 5 questions.
Diabetes Quizlet: 3 Quick Questions
Spot check your memory for these disease details.
Diabetes Drug Quiz: Do You Know Your Generics vs Trades?
Trade names often mask the essential nature of a medication, but some of the new agents that treat type 2 diabetes take it to a new level. Here, 5 chances to see what you know.
Five Top Papers From 2014 That Will Impact Your Practice
New drugs that treat stubborn illness seen often in primary care lead this group of Top 5 Papers for 2014. Type 2 diabetes, cryptogenic stroke, and hep-C are key targets.
By clicking Accept, you agree to become a member of the UBM Medica Community.